Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 3 | 1 |
| List of Figures | 4 | 1 |
| Report Guidance | 5 | 1 |
| Clinical Trials by Region | 6 | 8 |
| Clinical Trials and Average Enrollment by Country | 7 | 2 |
| Top Five Countries Contributing to Clinical Trials in Asia-Pacific | 9 | 1 |
| Top Five Countries Contributing to Clinical Trials in Europe | 10 | 1 |
| Top Countries Contributing to Clinical Trials in North America | 11 | 1 |
| Top Five Countries Contributing to Clinical Trials in Middle East and Africa | 12 | 1 |
| Top Five Countries Contributing to Clinical Trials in Central and South America | 13 | 1 |
| Clinical Trials by G7 Countries: Proportion of Atrial Fibrillation to Cardiovascular Clinical Trials | 14 | 1 |
| Clinical Trials by Phase in G7 Countries | 15 | 1 |
| Clinical Trials in G7 Countries by Trial Status | 16 | 1 |
| Clinical Trials by E7 Countries: Proportion of Atrial Fibrillation to Cardiovascular Clinical Trials | 17 | 1 |
| Clinical Trials by Phase in E7 Countries | 18 | 1 |
| Clinical Trials in E7 Countries by Trial Status | 19 | 1 |
| Clinical Trials by Phase | 20 | 2 |
| In Progress Trials by Phase | 21 | 1 |
| Clinical Trials by Trial Status | 22 | 1 |
| Clinical Trials by End Point Status | 23 | 1 |
| Subjects Recruited Over a Period of Time | 24 | 1 |
| Clinical Trials by Sponsor Type | 25 | 1 |
| Prominent Sponsors | 26 | 3 |
| Top Companies Participating in Atrial Fibrillation Therapeutics Clinical Trials | 27 | 2 |
| Prominent Drugs | 29 | 1 |
| Latest Clinical Trials News on Atrial Fibrillation | 30 | 10 |
| Aug 30, 2016: Trial results for anticoagulants for cardioversion in AF patients published | 30 | 1 |
| Aug 30, 2016: ENSURE-AF Data Support the Efficacy and Safety Profile of Daiichi Sankyo s Once-Daily LIXIANA in Patients with Atrial Fibrillation Undergoing Cardioversion | 30 | 1 |
| Aug 30, 2016: Latest data on dabigatran etexilate safety and effectiveness profile show low rates of bleeding and stroke in NVAF patients in routine clinical care | 31 | 1 |
| Aug 29, 2016: Real-World Data from Multiple Countries Continue to Reaffirm Positive Benefit-Risk Profile of Bayer's Xarelto in Everyday Clinical Practice | 32 | 1 |
| Aug 29, 2016: ESC Congress 2016 Late Breaking Science Registry: Latest Data on Pradaxa (dabigatran etexilate mesylate) Safety and Effectiveness Profile Show Low Rates of Bleeding and Stroke in NVAF Patients in Routine Clinical Care | 33 | 1 |
| Aug 24, 2016: Daiichi Sankyo Initiates ELDERCARE-AF Study of Anticoagulant Edoxaban | 34 | 1 |
| Aug 24, 2016: Data from Phase 3b ENSURE-AF Study Investigating Once-Daily SAVAYSA (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion Among 13 Daiichi Sankyo Clinical Presentations at ESC Congress 2016 | 34 | 2 |
| Aug 23, 2016: Bristol-Myers Squibb and Pfizer to Present New Eliquis (apixaban) Analyses at ESC Congress 2016 | 36 | 1 |
| Aug 22, 2016: New Real-World Evidence on Venous and Arterial Blood Clot Management including Bayer s Xarelto Accepted for Presentation at ESC Congress 2016 | 37 | 3 |
| Clinical Trial Profile Snapshots | 40 | 449 |
| Appendix | 489 | 4 |
| Abbreviations | 489 | 1 |
| Definitions | 489 | 1 |
| Research Methodology | 490 | 1 |
| Secondary Research | 490 | 1 |
| About GlobalData | 491 | 1 |
| Contact Us | 491 | 1 |
| Disclaimer | 491 | 1 |
| Source | 492 | 1 |